Clinical trial
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory…
NCT00216099 · Christopher Sweeney, MBBS, Other · Completed
Key facts
| NCT number | NCT00216099 |
|---|---|
| Title | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer |
| Official title | A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67 |
| Lead sponsor | Christopher Sweeney, MBBS, Other |
| Collaborators | Eli Lilly and Company Industry Walther Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Pemetrexed, Folic Acid, Vitamin B12 |
| Enrollment | 49 |
| Start date | Feb 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Jul 29, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: